This study investigates the role of type I interferons (IFN-I) in COVID-19 severity. Researchers found that reduced IFN-I responses are consistently associated with increased disease severity. They highlight the importance of using sensitive assays to measure IFN-I proteins and show that hospitalized patients exhibit impaired IFN-I induction upon immune stimulation, not solely due to autoantibodies. The study suggests that this impaired IFN-I response may explain the poor clinical response to IFN-I-based treatments in late-stage COVID-19 and proposes alternative therapeutic strategies.
Publisher
Nature Communications
Published On
Nov 25, 2022
Authors
Darragh Duffy
Tags
COVID-19
type I interferons
disease severity
immune response
therapeutic strategies
hospitalized patients
Related Publications
Explore these studies to deepen your understanding of the subject.
